Edgar Filing: IMARX THERAPEUTICS INC - Form 4

IMARX THER Form 4 August 02, 200		NC								
FORM	Л								PPROVAL	
	• UNITED	STATES					COMMISSION	N OMB Number:	3235-0287	
Check this b if no longer subject to Section 16. Form 4 or		Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES						Expires: Estimated burden hou response	urs per	
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940										
(Print or Type Resp	ponses)									
1. Name and Address of Reporting Person <u>*</u> Zakes Bradford			2. Issuer Name and Ticker or Trading Symbol IMARX THERAPEUTICS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
		[IMRX]					(Chi	eck all applicabl	6)	
(Last) (First) (Middle) C/O IMARX THERAPEUTICS, INC., 1635 EAST 18TH STREET			3. Date of Earliest Transaction(Month/Day/Year)07/31/2007			X Director 10% Owner X Officer (give title Other (specify below) below) President and CEO				
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) TUCSON, AZ 85719				1	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 					
(City)	(State)	(Zip)	Tab	le I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	Transaction Date onth/Day/Year)		Date, if	Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report	on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					Perso inform requir	ns who res nation cont red to resp ays a curre	spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					posed of, or convertible	Beneficially Owner securities)	đ		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	2
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	iorDerivative	Expiration Date	Underlying Securities	1

8 E

Edgar Filing: IMARX THERAPEUTICS INC - Form 4

Security (Instr. 3)	2		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		S (.
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	5
Stock Option (right to buy)	\$ 5	07/31/2007		А	41,666		<u>(1)</u>	07/31/2017	Common Stock	41,666	

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Zakes Bradford C/O IMARX THERAPEUTICS, INC. 1635 EAST 18TH STREET TUCSON, AZ 85719	Х		President and CEO	
Signatures				
Bradford Zakes by Kevin Ontiveros, Attorney-in-Fact		08/02/20)07	
**Signature of Reporting Person		Date		
Explanation of Respon	ses:			

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in four (4) equal installments on each of July 31, 2008, 2009, 2010 and 2011, and may be exercised prior to vesting, subject to certain rights of repurchase by the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.